이수앱지스
Financials
Valuation Metrics
이수앱지스's Market Cap is ₩1450B. At end of 2025 it was ₩2100B. Ranked #1042 of 2,421 in KR market (top 43%), #530 of 1,640 on KOSDAQ (top 32%), #119 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 52%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 144.96B KRW | KR#1,042/2,421 Sec#119/231 |
| Revenue | 51.04B KRW | KR#1,778/2,421 Sec#121/231 |
| Net Income | -8.18B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 154.19B KRW | KR#1,490/2,421 Sec#113/231 |
| Net Assets | 118.61B KRW | KR#1,300/2,421 Sec#102/231 |
| Employees | 190 | KR#1,134/2,421 Sec#93/231 |
| Value | ||
| P/B | 1.22x | KR#1,634/2,421 Sec#108/231 |
| P/S | 2.84x | KR#1,960/2,421 Sec#118/231 |
| FCF Yield | 4.63% | KR#869/2,421 Sec#47/231 |
| Profitability | ||
| ROE | -6.90% | KR#1,865/2,421 Sec#134/231 |
| ROA | -5.31% | KR#1,946/2,421 Sec#140/231 |
| Op. Margin | -20.07% | KR#2,122/2,421 Sec#145/231 |
| Revenue Growth | -14.10% | KR#2,020/2,421 Sec#183/231 |
| Earnings Growth | -127.71% | KR#1,182/2,421 Sec#75/231 |
| Financial Health | ||
| Debt Ratio | 29.99% | KR#591/2,421 Sec#68/231 |
| Total Debt | 19.32B KRW | KR#1,389/2,421 Sec#110/231 |
| FCF | 6.71B KRW | KR#826/2,421 Sec#53/231 |
| Cash | 23.04B KRW | KR#1,167/2,421 Sec#80/231 |
| Current Ratio | 2.35x | KR#735/2,421 Sec#87/231 |
| Performance | ||
| 1Y Return | -36.18% | KR#1,740/2,421 Sec#142/231 |
| 1M Return | 7.89% | KR#579/2,421 Sec#39/231 |
| From 52W High | -44.02% | KR#1,107/2,421 Sec#83/231 |
| 1Y MDD | -52.32% | KR#1,091/2,421 Sec#90/231 |
| Trading | ||
| Volume | 35,674 shares | KR#1,291/2,421 Sec#128/231 |
| Trading Value | 126.9M KRW | KR#1,452/2,421 Sec#147/231 |
| Foreign Own. | 1.72% | KR#1,741/2,421 Sec#166/231 |
| Per Share | ||
| EPS | -201 KRW | KR—/2,421 Sec—/231 |
| BPS | 2,909 KRW | KR#1,884/2,421 Sec#143/231 |
Company Info
Established in 2001, Isu Abxis is a specialized company that develops, manufactures, and sells biotechnology-based therapeutic antibodies and proteins, having been special listed on the KOSDAQ market in 2009. Its key therapeutic products include Abcertin, Pabagal, Clotynap, Feburain, Trientop, and Casavan, and it continues to grow in its unique field. The company is promoting export expansion and market diversification, notably by signing sales right contracts for Pabagal in 11 countries including Russia and Taiwan. Isu Abxis is also reviewing the development of therapeutic products for cancer and intractable diseases and is headquartered in Seongnam-si, Gyeonggi-do.